Novo Nordisk enters 2026 on the defense as it faces a ‘must-win’ battle in the U.S. market by CNBC Markets | January 1, 2026 12:11 pm | US Markets The FDA approval of the Wegovy pill highlights many of the key themes Novo Nordisk will have to face in 2026.
